Traws Pharma (TRAW)
NASDAQ:TRAW
Want to see TRAW full AI Analyst Report?
TRAW Stock Chart & Stats
$1.25
-$0.87(-9.63%)
At close: 4:00 PM EST
$1.25
-$0.87(-9.63%)
Day’s Range― - ―
52-Week Range$0.97 - $3.27
Previous CloseN/A
Volume35.69K
Average Volume (3M)206.36K
Market Cap
$11.78M
Enterprise Value$6.14M
Total Cash (Recent Filing)$3.82M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)1.0
Beta<0.01
Next Earnings
May 18, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding10,157,257
10 Day Avg. Volume403,079
30 Day Avg. Volume206,356
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-14.78
Price to Sales (P/S)3.33
P/FCF Ratio-0.45
Enterprise Value/Market Cap0.52
Enterprise Value/Revenue2.20
Enterprise Value/Gross Profit2.20
Enterprise Value/Ebitda-0.94
Forecast
1Y Price Target
$6.50Price Target Upside420.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.62
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Ratutrelvir Phase‑2 PoCDemonstrated clinical proof-of-concept materially de-risks the COVID antiviral program, supporting potential regulatory paths, partner interest, and commercial relevance. Durable clinical differentiation (fewer AEs, no rebounds) strengthens strategic optionality for licensing or stockpile inclusion over 2–6 months.
Tivoxavir Formulation & Challenge TrialA higher-exposure tablet plus an approved bridging study and planned U.K. human challenge trial create lasting product differentiation for once-monthly prophylaxis. These program advances improve probability of clinical success and future market positioning versus seasonal antivirals.
Up To $60M Contingent PIPE FinancingSecuring an upfront tranche and milestone-linked proceeds materially extends operational runway into Q1 2027 and ties capital flow to program milestones. This structure preserves near-term execution capability while aligning funding with clinical progress and de-risking immediate solvency concerns.
Bears Say
FDA IND Clinical HoldA toxicology-driven IND hold threatens U.S. development timelines and access to strategic stockpiles; resolving it requires additional studies and regulator engagement, raising costs and potentially delaying pivotal milestones and commercialization beyond 2026.
Weak Cash Flow & Negative EquityConsistent negative operating and free cash flow, a sharp 2025 cash burn and negative equity reduce financial flexibility and increase dependence on external financing. Over months this constrains R&D pacing, partnership leverage, and increases dilution risk if milestones slip.
Earnings Quality / Nonrecurring RevenueThe apparent 2025 profitability is tied to one-time licensing accounting and absence of prior IPR&D charges, not recurring operations. This undermines predictability of cash generation and complicates partner valuation or reimbursement discussions over the medium term.
Traws Pharma News
TRAW FAQ
What was Traws Pharma’s price range in the past 12 months?
Traws Pharma lowest stock price was $0.97 and its highest was $3.27 in the past 12 months.
What is Traws Pharma’s market cap?
Traws Pharma’s market cap is $11.78M.
When is Traws Pharma’s upcoming earnings report date?
Traws Pharma’s upcoming earnings report date is May 18, 2026 which is in 19 days.
How were Traws Pharma’s earnings last quarter?
Traws Pharma released its earnings results on Mar 12, 2026. The company reported -$0.82 earnings per share for the quarter, beating the consensus estimate of -$1.224 by $0.404.
Is Traws Pharma overvalued?
According to Wall Street analysts Traws Pharma’s price is currently Undervalued.
Does Traws Pharma pay dividends?
Traws Pharma does not currently pay dividends.
What is Traws Pharma’s EPS estimate?
Traws Pharma’s EPS estimate is -0.51.
How many shares outstanding does Traws Pharma have?
Traws Pharma has 10,157,257 shares outstanding.
What happened to Traws Pharma’s price movement after its last earnings report?
Traws Pharma reported an EPS of -$0.82 in its last earnings report, beating expectations of -$1.224. Following the earnings report the stock price went up 1.508%.
Which hedge fund is a major shareholder of Traws Pharma?
Currently, no hedge funds are holding shares in TRAW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Traws Pharma
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
TRAW Stock 12 Month Forecast
Average Price Target
$6.50
▲(420.00% Upside)
Technical Analysis
Ownership Overview
6.88% Insiders
1.11% Mutual Funds
28.86% Other Institutional Investors
62.61% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---